User:Ewingdo/sandbox/list of cardiology clinical trials

Early versus Late Intervention Trial with Estradiol (ELITE) -

Acute Coronary Syndrome / Coronary Artery Disease

ACCOAST - determine if pretreatment with prasugrel is superior to treatment with prasugrel selectively after percutaneous coronary intervention.^[1]
ASCERT - observational study comparing survival in patients undergoing PCI vs CABG.^[2]
Aspirin and heparin in acute unstable angina - ^[3]
ATLAS-ACS-2-TIMI-51 - ^[4]
AUGUSTUS - Apixaban and antiplatelet therapy for Afib + CAD^[5]
BARI - ^[6]
BARI-2D - ^[7]
BASKET-PROVE - Drug-eluting coronary stents vs bare-metal stents^[8]
CADILLAC -
CAPRIE - ^[9]
CHARISMA - ^[10]
CLARITY-TIMI 28 - Clopidogrel + aspirin and fibrinolysis in STEMI^[11]
COMMIT - Beta-blockers in patients with MI^[12]
COURAGE - PCI vs medical therapy for stable CAD^[13]
CURE - Clopidogrel + aspirin in NSTEMI^[14]
CURRENT-OASIS-7 -
DANAMI-2 - PCI vs fibrinolysis in MI^[15]
DIGAMI -
DIGAMI-2 -
EPHESUS -
ESPRIT
FAME - ^[16]
FAME-2 - ^[17]
FAME 3 - ^[18]
FREEDOM - Multivessel CAD in diabetics^[19]
GISSI-1 -
GISSI-2 -
GISSI-3 -
GISSI Prevention -
GUSTO - Thrombolysis for acute myocardial infarction^[20]
HEAT-PPCI -
HOPE - ACE-I effect on CV outcomes^[21]
HORIZONS-AMI -
ISCHEMIA - ^[22]
ISIS-1 -
ISIS-2 -
ISIS-4 -
MRFIT - randomized primary prevention trial to test the effect of a multifactor intervention program on mortality from coronary heart disease. Men were randomly assigned either to a special intervention program consisting of stepped-care treatment for hypertension, counseling for cigarette smoking, and dietary advice for lowering blood cholesterol levels, or to their usual sources of health care.^[23]
NORDISTEMI -
OASIS-5 -
OASIS-6 -
[[ONTARGET] -
ORBITA - ^[24]
PIONEER AF-PCI - Rivoraxaban and antiplatelet therapy for Afib + CAD^[25]
PLATO - Ticagrelor vs clopidogrel in ACS^[26]
PRAMI -
PRODIGY -
RITA-3 -
RIVAL -
SYNTAX - PCI vs CABG for severe CAD^[27]
TACTICS-TIMI-18 -
TAPAS -
TIMACS - Early vs delayed PCI in ACS^[28]
TIMI score study - ^[29]
TRILOGY-ACS -
TRITON-TIMI 38 - Prasugrel vs clopidogrel in ACS^[30]

Hypertension

ACCOMPLISH - Benazepril + amlodipine for hypertension
Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) - ACE-Is, CCBs, and thiazides for hypertension^[31]
DASH - Diet for hypertension
DASH-Sodium -
HYVET - Managing hypertension in the elderly
IDNT - ARBs for diabetic nephropathy
LIFE -
OmniCarb -
OmniHeart -
PROGRESS -
SHEP - Benefit of treating HTN to reduce stroke risk
Systolic Blood Pressure Intervention Trial (SPRINT) - Intensive BP control^[32]
Symplicity HTN-2 -
Symplicity HTN-3 -
Syst-Eur -
TOHP 1 - Non-pharmacological interventions for BP control
VALUE -

Lipids

LRC-CPPT -
SEAS -
ARBITER-6 -
SHARP -
Coronary Drug Project -
FATS -
HPS2-THRIVE -
VA-HIT -
FIELD -
CLEAR -
ODYSSEY OUTCOMES -
HOPE-3 -
LIPID -
AVERT -
LIPS -
ALLIANCE -
TNT -
AFCAPS/TexCAPs -
A to Z -
ACCORD -
AIM-HIGH (trial) - Niacin for HDL levels.^[33]
ALLHAT-LLT -
ASCOT-LLT/LLA -
ASTEROID -
AURORA -
CARE -
CARDS trial - ^[34]
CORONA trial - ^[35]
ENHANCE trial -^[36]
Helsinki Heart Study - landmark clinical trial conducted to assess the efficacy of gemfibrozil in reducing the incidence of coronary heart disease in middle-aged men with dyslipidemia.^[37]
HDL-Atherosclerosis Treatment Study (HATS) - a double-blind trial that studied people with coronary heart disease and compared a combination of simvastatin and niacin with antioxidant vitamin therapy.^[38]
Heart Protection Study - a randomized controlled trial that studied the cholesterol-lowering drug simvastatin and vitamin supplementation in people at risk of cardiovascular disease.^[39]
IDEAL -
IMPROVE-IT trial - ^[40]
JUPITER trial - clinical trial aimed at evaluating whether statins reduce heart attacks and strokes in people with normal cholesterol levels.^[41]
LIPID -
MEGA -
METEOR -
MIRACLE -
PROSPER -
PROVE-IT TIMI 22 - randomized, double-blind clinical trial that compared intensive vs. moderate-dose statin therapy immediately after a heart attack.^[42]
REVERSAL -
SATURN trial - ^[43]
Scandinavian_Simvastatin_Survival_Study (4S) - clinical trial that studied the use of the cholesterol-lowering drug simvastatin in people with moderately raised cholesterol and coronary heart disease.^[44]
SEARCH -
SPARCL -
West of Scotland Coronary Prevention Study (WOSCOPS) - randomized, double-blind, placebo-controlled clinical trial that compared the cholesterol-lowering drug pravastatin in patients with no previous history of a heart attack.^[45]

Heart Failure

A-HeFT - Isosorbide dinitrate and hydralazine for heart failure
BEAUTIFUL -
CARRESS-HF -
CHARM -
CIBIS-II -
COMET -
CONSENSUS - ACE-Is for heart failure
COPERNICUS - Carvedilol for heart failure
DAPA HF - Dapagliflozin in CHF
DIG - ^[46]
DOSE - Diuretics for acute heart failure
EMPEROR Reduced - Empagliflozin in CHF
EMPHASIS-HF - Eplerenone for heart failure
HARPS -
HEARTMATE II - LVAD for advanced HF
I-PRESERVE -
Multicenter Automatic Defibrillator Implantation Trial (MADIT) - implantable cardioverter defibrillator (or ICD) trials which investigate whether prophylactic ICD therapy in moderately high-risk coronary patients (in addition to conventional therapy) would significantly reduce death compared with patients treated with conventional therapy alone.
MADIT II - ICD for heart failure with reduced EF
MADIT CRT - CRT-D for heart failure with reduced EF
MERIT-HF - Metoprolol for heart failure
PARADIGM-HF - Sacubitril-valsartan for CHF^[47]
RALES - Spironolactone for heart failure
REMATCH -
SAVE - ACE-Is for LV dysfunction
SCD-HeFT -
SHIFT -
SOLVD -
STITCH -
Val-HEFT - ARB for heart failure
WARCF -

Arrhythmias

ACUTE - TEE for Afib cardioversion
AFFIRM - Rate control vs rhythm control for Afib
AFIRE - Rivaroxaban for Afib + stable CAD
APAF -
ARISTOTLE - Apixaban vs warfarin for Afib
ATHENA -
AUGUSTUS - Anticoagulation + DAPT for CAD
BRIDGE - Perioperative anticoagulation bridging for Afib
[[Cardiac Arrhythmia Suppression Trial[[ (CAST) - double-blind, randomized, controlled study designed to test the hypothesis that suppression of premature ventricular complexes (PVC) with class I antiarrhythmic agents after a myocardial infarction (MI) would reduce mortality.^[48]^[49]
CAST II - ^[50]
CASTLE AF - ^[51]
Early AF - ^[52]
EAST AFNET - ^[53]
LAAOS 3 -
MANTRA-PAF -
PALLAS -
PINNACLE FLX - ^[54]
PIONEER AF-PCI Rivaroxaban + DAPT for Afib + CAD
PRAGUE 17 -
PREVAIL -
PROTECT AF -
RACE-II -
RAFT-AF - ^[55]
RE-LY -
ROCKET-AF -
SPAF - ^[56]
SPAF-III - Warfarin dosing for Afib
SPAF-II -
START AF / STAR AF 2 -
STOP AF - ^[57]
SWISS APERO - ^[58]
ThermoCool-AF -

Valvular diseases

PARTNER A – TAVR in high-risk patients
PARTNER 3 – TAVR in low-risk patients
COAPT – Transcatheter mitral valve repair
EASE – Surgery for infective endocarditis

References

^ Montalescot, Gilles; Bolognese, Leonardo; Dudek, Dariusz; et al. (12 September 2013). "Pretreatment with Prasugrel in Non–ST-Segment Elevation Acute Coronary Syndromes". New England Journal of Medicine. 369 (11): 999–1010. doi:10.1056/NEJMoa1308075.
^ Weintraub, William S.; Grau-Sepulveda, Maria V.; Weiss, Jocelyn M.; et al. (19 April 2012). "Comparative Effectiveness of Revascularization Strategies". New England Journal of Medicine. 366 (16): 1467–1476. doi:10.1056/NEJMoa1110717.
^ Théroux, Pierre; Ouimet, Hélène; McCans, John; et al. (27 October 1988). "Aspirin, Heparin, or Both to Treat Acute Unstable Angina". New England Journal of Medicine. 319 (17): 1105–1111. doi:10.1056/NEJM198810273191701.
^ Mega, Jessica L.; Braunwald, Eugene; Wiviott, Stephen D.; et al. (5 January 2012). "Rivaroxaban in Patients with a Recent Acute Coronary Syndrome". New England Journal of Medicine. 366 (1): 9–19. doi:10.1056/NEJMoa1112277.
^ Lopes, Renato D.; Heizer, Gretchen; Aronson, Ronald; et al. (18 April 2019). "Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation". New England Journal of Medicine. 380 (16): 1509–1524. doi:10.1056/NEJMoa1817083.
^ Chaitman, Bernard R.; Rosen, Allan D.; Williams, David O.; et al. (7 October 1997). "Myocardial Infarction and Cardiac Mortality in the Bypass Angioplasty Revascularization Investigation (BARI) Randomized Trial". Circulation. 96 (7): 2162–2170. doi:10.1161/01.CIR.96.7.2162.
^ "A Randomized Trial of Therapies for Type 2 Diabetes and Coronary Artery Disease". New England Journal of Medicine. 360 (24): 2503–2515. 11 June 2009. doi:10.1056/NEJMoa0805796.
^ Kaiser, Christoph; Galatius, Soeren; Erne, Paul; et al. (9 December 2010). "Drug-Eluting versus Bare-Metal Stents in Large Coronary Arteries". New England Journal of Medicine. 363 (24): 2310–2319. doi:10.1056/NEJMoa1009406.
^ "A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)". The Lancet. 348 (9038): 1329–1339. November 1996. doi:10.1016/S0140-6736(96)09457-3.
^ Bhatt, Deepak L.; Fox, Keith A.A.; Hacke, Werner; et al. (20 April 2006). "Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Atherothrombotic Events". New England Journal of Medicine. 354 (16): 1706–1717. doi:10.1056/NEJMoa060989.
^ Sabatine, Marc S.; Cannon, Christopher P.; Gibson, C. Michael; et al. (24 March 2005). "Addition of Clopidogrel to Aspirin and Fibrinolytic Therapy for Myocardial Infarction with ST-Segment Elevation". New England Journal of Medicine. 352 (12): 1179–1189. doi:10.1056/NEJMoa050522.
^ Chen ZM, Pan HC, Chen YP, Peto R, Collins R, Jiang LX, Xie JX, Liu LS (November 2005). "Early intravenous then oral metoprolol in 45 852 patients with acute myocardial infarction: randomised placebo-controlled trial". The Lancet. 366 (9497): 1622–1632. doi:10.1016/S0140-6736(05)67661-1.
^ Boden, William E.; O'Rourke, Robert A.; Teo, Koon K.; et al. (12 April 2007). "Optimal Medical Therapy with or without PCI for Stable Coronary Disease". New England Journal of Medicine. 356 (15): 1503–1516. doi:10.1056/NEJMoa070829.
^ "Effects of Clopidogrel in Addition to Aspirin in Patients with Acute Coronary Syndromes without ST-Segment Elevation". New England Journal of Medicine. 345 (7): 494–502. 16 August 2001. doi:10.1056/NEJMoa010746.
^ Andersen, Henning R.; Nielsen, Torsten T.; Rasmussen, Klaus; et al. (21 August 2003). "A Comparison of Coronary Angioplasty with Fibrinolytic Therapy in Acute Myocardial Infarction". New England Journal of Medicine. 349 (8): 733–742. doi:10.1056/NEJMoa025142.
^ Tonino, Pim A.L.; De Bruyne, Bernard; Pijls, Nico H.J.; et al. (15 January 2009). "Fractional Flow Reserve versus Angiography for Guiding Percutaneous Coronary Intervention". New England Journal of Medicine. 360 (3): 213–224. doi:10.1056/NEJMoa0807611.
^ Xaplanteris, Panagiotis; Fournier, Stephane; Pijls, Nico H.J.; et al. (19 July 2018). "Five-Year Outcomes with PCI Guided by Fractional Flow Reserve". New England Journal of Medicine. 379 (3): 250–259. doi:10.1056/NEJMoa1803538.
^ Fearon, William F.; Zimmermann, Frederik M.; De Bruyne, Bernard; et al. (13 January 2022). "Fractional Flow Reserve–Guided PCI as Compared with Coronary Bypass Surgery". New England Journal of Medicine. 386 (2): 128–137. doi:10.1056/NEJMoa2112299.
^ Farkouh, Michael E.; Domanski, Michael; Sleeper, Lynn A.; et al. (20 December 2012). "Strategies for Multivessel Revascularization in Patients with Diabetes". New England Journal of Medicine. 367 (25): 2375–2384. doi:10.1056/NEJMoa1211585.
^ "An International Randomized Trial Comparing Four Thrombolytic Strategies for Acute Myocardial Infarction". New England Journal of Medicine. 329 (10): 673–682. 2 September 1993. doi:10.1056/NEJM199309023291001.
^ Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G (20 January 2000). "Effects of an Angiotensin-Converting–Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk Patients". New England Journal of Medicine. 342 (3): 145–153. doi:10.1056/NEJM200001203420301.
^ Maron, David J.; Hochman, Judith S.; Reynolds, Harmony R.; et al. (9 April 2020). "Initial Invasive or Conservative Strategy for Stable Coronary Disease". New England Journal of Medicine. 382 (15): 1395–1407. doi:10.1056/NEJMoa1915922.
^ "Multiple risk factor intervention trial. Risk factor changes and mortality results. Multiple Risk Factor Intervention Trial Research Group". JAMA. 248 (12): 1465–77. 24 September 1982. PMID 7050440.
^ Al-Lamee, Rasha; Thompson, David; Dehbi, Hakim-Moulay; et al. (January 2018). "Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial". The Lancet. 391 (10115): 31–40. doi:10.1016/S0140-6736(17)32714-9.
^ Gibson, C. Michael; Mehran, Roxana; Bode, Christoph; et al. (22 December 2016). "Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI". New England Journal of Medicine. 375 (25): 2423–2434. doi:10.1056/NEJMoa1611594.
^ Wallentin, Lars; Becker, Richard C.; Budaj, Andrzej; et al. (10 September 2009). "Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes". New England Journal of Medicine. 361 (11): 1045–1057. doi:10.1056/NEJMoa0904327.
^ Serruys, Patrick W.; Morice, Marie-Claude; Kappetein, A. Pieter; et al. (5 March 2009). "Percutaneous Coronary Intervention versus Coronary-Artery Bypass Grafting for Severe Coronary Artery Disease". New England Journal of Medicine. 360 (10): 961–972. doi:10.1056/NEJMoa0804626.
^ Mehta, Shamir R.; Granger, Christopher B.; Boden, William E.; et al. (21 May 2009). "Early versus Delayed Invasive Intervention in Acute Coronary Syndromes". New England Journal of Medicine. 360 (21): 2165–2175. doi:10.1056/NEJMoa0807986.
^ Antman, Elliott M.; Cohen, Marc; Bernink, Peter J. L. M.; et al. (16 August 2000). "The TIMI Risk Score for Unstable Angina/Non–ST Elevation MI: A Method for Prognostication and Therapeutic Decision Making". JAMA. 284 (7): 835. doi:10.1001/jama.284.7.835.
^ Wiviott, Stephen D.; Braunwald, Eugene; McCabe, Carolyn H.; et al. (15 November 2007). "Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes". New England Journal of Medicine. 357 (20): 2001–2015. doi:10.1056/NEJMoa0706482.
^ "Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)". JAMA: The Journal of the American Medical Association. 288 (23): 2981–2997. 18 December 2002. doi:10.1001/jama.288.23.2981.
^ "A Randomized Trial of Intensive versus Standard Blood-Pressure Control". New England Journal of Medicine. 373 (22): 2103–2116. 26 November 2015. doi:10.1056/NEJMoa1511939.
^ Boden, William E; Probstfield, Jeffrey L; Anderson, Todd; Chaitman, Bernard R; Desvignes-Nickens, Patrice; Koprowicz, Kent; McBride, Ruth; Teo, Koon; Weintraub, William (15 December 2011). "Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy". New England Journal of Medicine. 365 (24): 2255–2267. doi:10.1056/nejmoa1107579.
^ Colhoun, Helen M; Betteridge, D John; Durrington, Paul N; et al. (August 2004). "Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial". The Lancet. 364 (9435): 685–696. doi:10.1016/S0140-6736(04)16895-5.
^ Kjekshus, John; Apetrei, Eduard; Barrios, Vivencio; et al. (29 November 2007). "Rosuvastatin in Older Patients with Systolic Heart Failure". New England Journal of Medicine. 357 (22): 2248–2261. doi:10.1056/NEJMoa0706201.
^ Kastelein, John J.P.; Akdim, Fatima; Stroes, Erik S.G.; et al. (3 April 2008). "Simvastatin with or without Ezetimibe in Familial Hypercholesterolemia". New England Journal of Medicine. 358 (14): 1431–1443. doi:10.1056/NEJMoa0800742.
^ Frick, M. Heikki; Elo, Olli; Haapa, Kauko; et al. (12 November 1987). "Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with Dyslipidemia". New England Journal of Medicine. 317 (20): 1237–1245. doi:10.1056/NEJM198711123172001.
^ Kastelein, John J.P.; Akdim, Fatima; Stroes, Erik S.G.; et al. (3 April 2008). "Simvastatin with or without Ezetimibe in Familial Hypercholesterolemia". New England Journal of Medicine. 358 (14): 1431–1443. doi:10.1056/NEJMoa0800742.
^ "MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo controlled trial". The Lancet. 360 (9326): 7–22. July 2002. doi:10.1016/S0140-6736(02)09327-3.
^ Cannon, Christopher P.; Blazing, Michael A.; Giugliano, Robert P.; et al. (18 June 2015). "Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes". New England Journal of Medicine. 372 (25): 2387–2397. doi:10.1056/NEJMoa1410489.
^ Ridker, Paul M; Danielson, Eleanor; Fonseca, Francisco A.H.; et al. (20 November 2008). "Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein". New England Journal of Medicine. 359 (21): 2195–2207. doi:10.1056/NEJMoa0807646.
^ Cannon, Christopher P.; Braunwald, Eugene; McCabe, Carolyn H.; et al. (8 April 2004). "Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes". New England Journal of Medicine. 350 (15): 1495–1504. doi:10.1056/NEJMoa040583.
^ Nicholls, Stephen J.; Ballantyne, Christie M.; Barter, Philip J.; et al. (December 2011). "Effect of Two Intensive Statin Regimens on Progression of Coronary Disease". New England Journal of Medicine. 365 (22): 2078–2087. doi:10.1056/NEJMoa1110874.
^ "Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)". Lancet (London, England). 344 (8934): 1383–9. 19 November 1994. PMID 7968073.
^ Shepherd, James; Cobbe, Stuart M.; Ford, Ian; et al. (16 November 1995). "Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia". New England Journal of Medicine. 333 (20): 1301–1308. doi:10.1056/NEJM199511163332001.
^ "The Effect of Digoxin on Mortality and Morbidity in Patients with Heart Failure". New England Journal of Medicine. 336 (8): 525–533. 20 February 1997. doi:10.1056/NEJM199702203360801.
^ McMurray, John J.V.; Packer, Milton; Desai, Akshay S.; et al. (11 September 2014). "Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure". New England Journal of Medicine. 371 (11): 993–1004. doi:10.1056/NEJMoa1409077.
^ "Preliminary Report: Effect of Encainide and Flecainide on Mortality in a Randomized Trial of Arrhythmia Suppression after Myocardial Infarction". New England Journal of Medicine. 321 (6): 406–412. 10 August 1989. doi:10.1056/NEJM198908103210629.
^ Echt, Debra S.; Liebson, Philip R.; Mitchell, L. Brent; et al. (21 March 1991). "Mortality and Morbidity in Patients Receiving Encainide, Flecainide, or Placebo: The Cardiac Arrhythmia Suppression Trial". New England Journal of Medicine. 324 (12): 781–788. doi:10.1056/NEJM199103213241201.
^ "Effect of the Antiarrhythmic Agent Moricizine on Survival after Myocardial Infarction". New England Journal of Medicine. 327 (4): 227–233. 23 July 1992. doi:10.1056/NEJM199207233270403.
^ Marrouche, Nassir F.; Brachmann, Johannes; Andresen, Dietrich; et al. (February 2018). "Catheter Ablation for Atrial Fibrillation with Heart Failure". New England Journal of Medicine. 378 (5): 417–427. doi:10.1056/NEJMoa1707855.
^ Andrade, Jason G.; Wells, George A.; Deyell, Marc W.; et al. (28 January 2021). "Cryoablation or Drug Therapy for Initial Treatment of Atrial Fibrillation". New England Journal of Medicine. 384 (4): 305–315. doi:10.1056/NEJMoa2029980.
^ Kirchhof, Paulus; Camm, A. John; Goette, Andreas; et al. (1 October 2020). "Early Rhythm-Control Therapy in Patients with Atrial Fibrillation". New England Journal of Medicine. 383 (14): 1305–1316. doi:10.1056/NEJMoa2019422.
^ Kar, Saibal; Doshi, Shephal K.; Sadhu, Ashish; et al. (4 May 2021). "Primary Outcome Evaluation of a Next-Generation Left Atrial Appendage Closure Device: Results From the PINNACLE FLX Trial". Circulation. 143 (18): 1754–1762. doi:10.1161/CIRCULATIONAHA.120.050117.
^ Parkash, Ratika; Wells, George A.; Rouleau, Jean; et al. (7 June 2022). "Randomized Ablation-Based Rhythm-Control Versus Rate-Control Trial in Patients With Heart Failure and Atrial Fibrillation: Results from the RAFT-AF trial". Circulation. 145 (23): 1693–1704. doi:10.1161/CIRCULATIONAHA.121.057095.
^ "Stroke Prevention in Atrial Fibrillation Study. Final results". Circulation. 84 (2): 527–539. August 1991. doi:10.1161/01.CIR.84.2.527.
^ Wazni, Oussama M.; Dandamudi, Gopi; Sood, Nitesh; et al. (28 January 2021). "Cryoballoon Ablation as Initial Therapy for Atrial Fibrillation". New England Journal of Medicine. 384 (4): 316–324. doi:10.1056/NEJMoa2029554.
^ Galea, Roberto; De Marco, Federico; Meneveau, Nicolas; et al. (8 March 2022). "Amulet or Watchman Device for Percutaneous Left Atrial Appendage Closure: Primary Results of the SWISS-APERO Randomized Clinical Trial". Circulation. 145 (10): 724–738. doi:10.1161/CIRCULATIONAHA.121.057859.

External links

Myat, Aung; Gershlick, Anthony H., eds. (2012). Landmark papers in cardiovascular medicine (First ed.). Oxford, United Kingdom: Oxford University Press. ISBN 978-0-19-959476-4.

[1] Montalescot, Gilles; Bolognese, Leonardo; Dudek, Dariusz; et al. (12 September 2013). "Pretreatment with Prasugrel in Non–ST-Segment Elevation Acute Coronary Syndromes". New England Journal of Medicine. 369 (11): 999–1010. doi:10.1056/NEJMoa1308075.

[2] Weintraub, William S.; Grau-Sepulveda, Maria V.; Weiss, Jocelyn M.; et al. (19 April 2012). "Comparative Effectiveness of Revascularization Strategies". New England Journal of Medicine. 366 (16): 1467–1476. doi:10.1056/NEJMoa1110717.

[3] Théroux, Pierre; Ouimet, Hélène; McCans, John; et al. (27 October 1988). "Aspirin, Heparin, or Both to Treat Acute Unstable Angina". New England Journal of Medicine. 319 (17): 1105–1111. doi:10.1056/NEJM198810273191701.

[4] Mega, Jessica L.; Braunwald, Eugene; Wiviott, Stephen D.; et al. (5 January 2012). "Rivaroxaban in Patients with a Recent Acute Coronary Syndrome". New England Journal of Medicine. 366 (1): 9–19. doi:10.1056/NEJMoa1112277.

[5] Lopes, Renato D.; Heizer, Gretchen; Aronson, Ronald; et al. (18 April 2019). "Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation". New England Journal of Medicine. 380 (16): 1509–1524. doi:10.1056/NEJMoa1817083.

[6] Chaitman, Bernard R.; Rosen, Allan D.; Williams, David O.; et al. (7 October 1997). "Myocardial Infarction and Cardiac Mortality in the Bypass Angioplasty Revascularization Investigation (BARI) Randomized Trial". Circulation. 96 (7): 2162–2170. doi:10.1161/01.CIR.96.7.2162.

[7] "A Randomized Trial of Therapies for Type 2 Diabetes and Coronary Artery Disease". New England Journal of Medicine. 360 (24): 2503–2515. 11 June 2009. doi:10.1056/NEJMoa0805796.

[8] Kaiser, Christoph; Galatius, Soeren; Erne, Paul; et al. (9 December 2010). "Drug-Eluting versus Bare-Metal Stents in Large Coronary Arteries". New England Journal of Medicine. 363 (24): 2310–2319. doi:10.1056/NEJMoa1009406.

[9] "A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)". The Lancet. 348 (9038): 1329–1339. November 1996. doi:10.1016/S0140-6736(96)09457-3.

[10] Bhatt, Deepak L.; Fox, Keith A.A.; Hacke, Werner; et al. (20 April 2006). "Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Atherothrombotic Events". New England Journal of Medicine. 354 (16): 1706–1717. doi:10.1056/NEJMoa060989.

[11] Sabatine, Marc S.; Cannon, Christopher P.; Gibson, C. Michael; et al. (24 March 2005). "Addition of Clopidogrel to Aspirin and Fibrinolytic Therapy for Myocardial Infarction with ST-Segment Elevation". New England Journal of Medicine. 352 (12): 1179–1189. doi:10.1056/NEJMoa050522.

[12] Chen ZM, Pan HC, Chen YP, Peto R, Collins R, Jiang LX, Xie JX, Liu LS (November 2005). "Early intravenous then oral metoprolol in 45 852 patients with acute myocardial infarction: randomised placebo-controlled trial". The Lancet. 366 (9497): 1622–1632. doi:10.1016/S0140-6736(05)67661-1.

[13] Boden, William E.; O'Rourke, Robert A.; Teo, Koon K.; et al. (12 April 2007). "Optimal Medical Therapy with or without PCI for Stable Coronary Disease". New England Journal of Medicine. 356 (15): 1503–1516. doi:10.1056/NEJMoa070829.

[14] "Effects of Clopidogrel in Addition to Aspirin in Patients with Acute Coronary Syndromes without ST-Segment Elevation". New England Journal of Medicine. 345 (7): 494–502. 16 August 2001. doi:10.1056/NEJMoa010746.

[15] Andersen, Henning R.; Nielsen, Torsten T.; Rasmussen, Klaus; et al. (21 August 2003). "A Comparison of Coronary Angioplasty with Fibrinolytic Therapy in Acute Myocardial Infarction". New England Journal of Medicine. 349 (8): 733–742. doi:10.1056/NEJMoa025142.

[16] Tonino, Pim A.L.; De Bruyne, Bernard; Pijls, Nico H.J.; et al. (15 January 2009). "Fractional Flow Reserve versus Angiography for Guiding Percutaneous Coronary Intervention". New England Journal of Medicine. 360 (3): 213–224. doi:10.1056/NEJMoa0807611.

[17] Xaplanteris, Panagiotis; Fournier, Stephane; Pijls, Nico H.J.; et al. (19 July 2018). "Five-Year Outcomes with PCI Guided by Fractional Flow Reserve". New England Journal of Medicine. 379 (3): 250–259. doi:10.1056/NEJMoa1803538.

[18] Fearon, William F.; Zimmermann, Frederik M.; De Bruyne, Bernard; et al. (13 January 2022). "Fractional Flow Reserve–Guided PCI as Compared with Coronary Bypass Surgery". New England Journal of Medicine. 386 (2): 128–137. doi:10.1056/NEJMoa2112299.

[19] Farkouh, Michael E.; Domanski, Michael; Sleeper, Lynn A.; et al. (20 December 2012). "Strategies for Multivessel Revascularization in Patients with Diabetes". New England Journal of Medicine. 367 (25): 2375–2384. doi:10.1056/NEJMoa1211585.

[20] "An International Randomized Trial Comparing Four Thrombolytic Strategies for Acute Myocardial Infarction". New England Journal of Medicine. 329 (10): 673–682. 2 September 1993. doi:10.1056/NEJM199309023291001.

[21] Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G (20 January 2000). "Effects of an Angiotensin-Converting–Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk Patients". New England Journal of Medicine. 342 (3): 145–153. doi:10.1056/NEJM200001203420301.

[22] Maron, David J.; Hochman, Judith S.; Reynolds, Harmony R.; et al. (9 April 2020). "Initial Invasive or Conservative Strategy for Stable Coronary Disease". New England Journal of Medicine. 382 (15): 1395–1407. doi:10.1056/NEJMoa1915922.

[23] "Multiple risk factor intervention trial. Risk factor changes and mortality results. Multiple Risk Factor Intervention Trial Research Group". JAMA. 248 (12): 1465–77. 24 September 1982. PMID 7050440.

[24] Al-Lamee, Rasha; Thompson, David; Dehbi, Hakim-Moulay; et al. (January 2018). "Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial". The Lancet. 391 (10115): 31–40. doi:10.1016/S0140-6736(17)32714-9.

[25] Gibson, C. Michael; Mehran, Roxana; Bode, Christoph; et al. (22 December 2016). "Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI". New England Journal of Medicine. 375 (25): 2423–2434. doi:10.1056/NEJMoa1611594.

[26] Wallentin, Lars; Becker, Richard C.; Budaj, Andrzej; et al. (10 September 2009). "Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes". New England Journal of Medicine. 361 (11): 1045–1057. doi:10.1056/NEJMoa0904327.

[27] Serruys, Patrick W.; Morice, Marie-Claude; Kappetein, A. Pieter; et al. (5 March 2009). "Percutaneous Coronary Intervention versus Coronary-Artery Bypass Grafting for Severe Coronary Artery Disease". New England Journal of Medicine. 360 (10): 961–972. doi:10.1056/NEJMoa0804626.

[28] Mehta, Shamir R.; Granger, Christopher B.; Boden, William E.; et al. (21 May 2009). "Early versus Delayed Invasive Intervention in Acute Coronary Syndromes". New England Journal of Medicine. 360 (21): 2165–2175. doi:10.1056/NEJMoa0807986.

[29] Antman, Elliott M.; Cohen, Marc; Bernink, Peter J. L. M.; et al. (16 August 2000). "The TIMI Risk Score for Unstable Angina/Non–ST Elevation MI: A Method for Prognostication and Therapeutic Decision Making". JAMA. 284 (7): 835. doi:10.1001/jama.284.7.835.

[30] Wiviott, Stephen D.; Braunwald, Eugene; McCabe, Carolyn H.; et al. (15 November 2007). "Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes". New England Journal of Medicine. 357 (20): 2001–2015. doi:10.1056/NEJMoa0706482.

[31] "Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)". JAMA: The Journal of the American Medical Association. 288 (23): 2981–2997. 18 December 2002. doi:10.1001/jama.288.23.2981.

[32] "A Randomized Trial of Intensive versus Standard Blood-Pressure Control". New England Journal of Medicine. 373 (22): 2103–2116. 26 November 2015. doi:10.1056/NEJMoa1511939.

[33] Boden, William E; Probstfield, Jeffrey L; Anderson, Todd; Chaitman, Bernard R; Desvignes-Nickens, Patrice; Koprowicz, Kent; McBride, Ruth; Teo, Koon; Weintraub, William (15 December 2011). "Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy". New England Journal of Medicine. 365 (24): 2255–2267. doi:10.1056/nejmoa1107579.

[34] Colhoun, Helen M; Betteridge, D John; Durrington, Paul N; et al. (August 2004). "Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial". The Lancet. 364 (9435): 685–696. doi:10.1016/S0140-6736(04)16895-5.

[35] Kjekshus, John; Apetrei, Eduard; Barrios, Vivencio; et al. (29 November 2007). "Rosuvastatin in Older Patients with Systolic Heart Failure". New England Journal of Medicine. 357 (22): 2248–2261. doi:10.1056/NEJMoa0706201.

[36] Kastelein, John J.P.; Akdim, Fatima; Stroes, Erik S.G.; et al. (3 April 2008). "Simvastatin with or without Ezetimibe in Familial Hypercholesterolemia". New England Journal of Medicine. 358 (14): 1431–1443. doi:10.1056/NEJMoa0800742.

[37] Frick, M. Heikki; Elo, Olli; Haapa, Kauko; et al. (12 November 1987). "Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with Dyslipidemia". New England Journal of Medicine. 317 (20): 1237–1245. doi:10.1056/NEJM198711123172001.

[38] Kastelein, John J.P.; Akdim, Fatima; Stroes, Erik S.G.; et al. (3 April 2008). "Simvastatin with or without Ezetimibe in Familial Hypercholesterolemia". New England Journal of Medicine. 358 (14): 1431–1443. doi:10.1056/NEJMoa0800742.

[39] "MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo controlled trial". The Lancet. 360 (9326): 7–22. July 2002. doi:10.1016/S0140-6736(02)09327-3.

[40] Cannon, Christopher P.; Blazing, Michael A.; Giugliano, Robert P.; et al. (18 June 2015). "Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes". New England Journal of Medicine. 372 (25): 2387–2397. doi:10.1056/NEJMoa1410489.

[41] Ridker, Paul M; Danielson, Eleanor; Fonseca, Francisco A.H.; et al. (20 November 2008). "Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein". New England Journal of Medicine. 359 (21): 2195–2207. doi:10.1056/NEJMoa0807646.

[42] Cannon, Christopher P.; Braunwald, Eugene; McCabe, Carolyn H.; et al. (8 April 2004). "Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes". New England Journal of Medicine. 350 (15): 1495–1504. doi:10.1056/NEJMoa040583.

[43] Nicholls, Stephen J.; Ballantyne, Christie M.; Barter, Philip J.; et al. (December 2011). "Effect of Two Intensive Statin Regimens on Progression of Coronary Disease". New England Journal of Medicine. 365 (22): 2078–2087. doi:10.1056/NEJMoa1110874.

[44] "Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)". Lancet (London, England). 344 (8934): 1383–9. 19 November 1994. PMID 7968073.

[45] Shepherd, James; Cobbe, Stuart M.; Ford, Ian; et al. (16 November 1995). "Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia". New England Journal of Medicine. 333 (20): 1301–1308. doi:10.1056/NEJM199511163332001.

[46] "The Effect of Digoxin on Mortality and Morbidity in Patients with Heart Failure". New England Journal of Medicine. 336 (8): 525–533. 20 February 1997. doi:10.1056/NEJM199702203360801.

[47] McMurray, John J.V.; Packer, Milton; Desai, Akshay S.; et al. (11 September 2014). "Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure". New England Journal of Medicine. 371 (11): 993–1004. doi:10.1056/NEJMoa1409077.

[48] "Preliminary Report: Effect of Encainide and Flecainide on Mortality in a Randomized Trial of Arrhythmia Suppression after Myocardial Infarction". New England Journal of Medicine. 321 (6): 406–412. 10 August 1989. doi:10.1056/NEJM198908103210629.

[49] Echt, Debra S.; Liebson, Philip R.; Mitchell, L. Brent; et al. (21 March 1991). "Mortality and Morbidity in Patients Receiving Encainide, Flecainide, or Placebo: The Cardiac Arrhythmia Suppression Trial". New England Journal of Medicine. 324 (12): 781–788. doi:10.1056/NEJM199103213241201.

[50] "Effect of the Antiarrhythmic Agent Moricizine on Survival after Myocardial Infarction". New England Journal of Medicine. 327 (4): 227–233. 23 July 1992. doi:10.1056/NEJM199207233270403.

[51] Marrouche, Nassir F.; Brachmann, Johannes; Andresen, Dietrich; et al. (February 2018). "Catheter Ablation for Atrial Fibrillation with Heart Failure". New England Journal of Medicine. 378 (5): 417–427. doi:10.1056/NEJMoa1707855.

[52] Andrade, Jason G.; Wells, George A.; Deyell, Marc W.; et al. (28 January 2021). "Cryoablation or Drug Therapy for Initial Treatment of Atrial Fibrillation". New England Journal of Medicine. 384 (4): 305–315. doi:10.1056/NEJMoa2029980.

[53] Kirchhof, Paulus; Camm, A. John; Goette, Andreas; et al. (1 October 2020). "Early Rhythm-Control Therapy in Patients with Atrial Fibrillation". New England Journal of Medicine. 383 (14): 1305–1316. doi:10.1056/NEJMoa2019422.

[54] Kar, Saibal; Doshi, Shephal K.; Sadhu, Ashish; et al. (4 May 2021). "Primary Outcome Evaluation of a Next-Generation Left Atrial Appendage Closure Device: Results From the PINNACLE FLX Trial". Circulation. 143 (18): 1754–1762. doi:10.1161/CIRCULATIONAHA.120.050117.

[55] Parkash, Ratika; Wells, George A.; Rouleau, Jean; et al. (7 June 2022). "Randomized Ablation-Based Rhythm-Control Versus Rate-Control Trial in Patients With Heart Failure and Atrial Fibrillation: Results from the RAFT-AF trial". Circulation. 145 (23): 1693–1704. doi:10.1161/CIRCULATIONAHA.121.057095.

[56] "Stroke Prevention in Atrial Fibrillation Study. Final results". Circulation. 84 (2): 527–539. August 1991. doi:10.1161/01.CIR.84.2.527.

[57] Wazni, Oussama M.; Dandamudi, Gopi; Sood, Nitesh; et al. (28 January 2021). "Cryoballoon Ablation as Initial Therapy for Atrial Fibrillation". New England Journal of Medicine. 384 (4): 316–324. doi:10.1056/NEJMoa2029554.

[58] Galea, Roberto; De Marco, Federico; Meneveau, Nicolas; et al. (8 March 2022). "Amulet or Watchman Device for Percutaneous Left Atrial Appendage Closure: Primary Results of the SWISS-APERO Randomized Clinical Trial". Circulation. 145 (10): 724–738. doi:10.1161/CIRCULATIONAHA.121.057859.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

[11]

[12]

[13]

[14]

[15]

[16]

[17]

[18]

[19]

[20]

[21]

[22]

[23]

[24]

[25]

[26]

[27]

[28]

[29]

[30]

[31]

[32]

[33]

[34]

[35]

[36]

[37]

[38]

[39]

[40]

[41]

[42]

[43]

[44]

[45]

[46]

[47]

[48]

[49]

[50]

[51]

[52]

[53]

[54]

[55]

[56]

[57]

[58]

User:Ewingdo/sandbox/list of cardiology clinical trials

Contents

Acute Coronary Syndrome / Coronary Artery Disease

Hypertension

Lipids

Heart Failure

Arrhythmias

Valvular diseases

See also

References

External links